AstraZeneca expands StarPharma deal for cancer drug delivery tech

DEP delivery tech--Courtesy of StarPharma

AstraZeneca ($AZN) has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline, according to a release. StarPharma's DEP delivery tech, which uses dendrimers to carry drugs to a targeted receptor, has been used to deliver the cancer drug docetaxel most often in the past, but the companies said back at the outset of their agreement that they would not be focusing their efforts there. Under the deal, AstraZeneca is set to provide funding for preclinical research conducted jointly. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…